August 4, 2022
Janssen Pharmaceutical’s CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) cleared the review of a key Japanese health ministry advisory committee on August 3, along with a label expansion for Novartis’ first-in-class product Kymriah (tisagenlecleucel). The Pharmaceutical Affairs and Food Sanitation Council’s...read more